Valneva SE (NASDAQ:VALN) Sees Significant Drop in Short Interest

Valneva SE (NASDAQ:VALN) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 15,900 shares, a drop of 34.6% from the December 15th total of 24,300 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 38,300 shares, the short-interest ratio is currently 0.4 days.

Valneva Trading Down 2.1 %

VALN stock traded down $0.09 during mid-day trading on Thursday, hitting $4.22. 854 shares of the company were exchanged, compared to its average volume of 39,404. The business has a fifty day simple moving average of $4.38 and a 200-day simple moving average of $5.91. The firm has a market capitalization of $342.92 million, a P/E ratio of -32.46 and a beta of 1.93. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on shares of Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, October 11th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its stake in Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 at the end of the most recent quarter. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.